



Neurocrine Biosciences To Present At The 26th Annual Roth Conference

March 4, 2014

Live Audio Webcast will be on March 11, 2014

SAN DIEGO, March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.

The live presentation takes place on Tuesday, March 11 at 9:30am PT (12:30pm ET). The presentation will be webcast and may be accessed on the Company's website at <http://www.neurocrine.com>.

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

SOURCE Neurocrine Biosciences, Inc.

Investor Relations, (858) 617-7600